![](https://investorshub.advfn.com/uicon/496813.png?cb=1559636125)
Friday, January 31, 2020 8:44:33 AM
"at a ratio of not less than 1-for-2, and not greater than 1-for-60, with the exact ratio and effective time of the reverse stock split to be determined by the Company’s Board of Directors as described in the Company’s Proxy Statement filed with the Securities and Exchange Commission on Schedule 14A on December 23, 2019."
Flip it, do not marry it
Recent GNPX News
- Genprex to Present at the 2024 BIO International Convention • PR Newswire (US) • 05/30/2024 12:31:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/20/2024 08:35:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:15:54 PM
- Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer • PR Newswire (US) • 05/14/2024 12:31:00 PM
- Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors • PR Newswire (US) • 05/13/2024 12:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:11:07 PM
- Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner • PR Newswire (US) • 05/08/2024 10:08:00 PM
- Genprex to Present and Participate at Upcoming May Investor and Industry Conferences • PR Newswire (US) • 05/01/2024 12:31:00 PM
- Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting • PR Newswire (US) • 04/09/2024 12:31:00 PM
- Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer • PR Newswire (US) • 04/03/2024 12:31:00 PM
- Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System • PR Newswire (US) • 04/02/2024 12:31:00 PM
- Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 03/22/2024 08:10:00 PM
- Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 03/19/2024 05:24:00 PM
- Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 03/19/2024 12:36:00 PM
- Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers • PR Newswire (US) • 03/12/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 02:18:38 PM
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting • PR Newswire (US) • 03/06/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 01:45:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:34:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:32:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:28:09 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:14:47 PM
- Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators • PR Newswire (US) • 02/07/2024 01:15:00 PM
- Genprex to Present at Upcoming BIO CEO & Investor Conference • PR Newswire (US) • 02/06/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 01:15:59 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM